- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00312702
Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America
May 15, 2018 updated by: U.S. Army Medical Research and Development Command
A Phase I/IIa Controlled Study of the Safety, Immunogenicity and Preliminary Efficacy of FMP011/AS02A Candidate Malaria Vaccine in Malaria-naive Adults Living in the United States
Phase I/II Trial of a Malaria Vaccine, FMP011/AS01B, in Adults Living in the United States of America.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
- Controlled challenge, Phase I/IIa WRAIR study.
- Healthy, malaria-naive adults aged 18 - 50 years.
- 2 groups, 5 subjects in group A (10µg dose) and 15 subjects in group B (50µg dose).
- Control: none for immunization phase; infectivity controls for challenge and rechallenge phases. Six infectivity controls per day of challenge will be enrolled for the challenge phases, with 3 alternates available for challenge if needed.
- Vaccination schedule of 0, 1 months.
- Challenge of up to 15 subjects in Group B.
- Contingent upon short term efficacy, rechallenge of initially protected subjects 6 months (+/- 2 months) after second dose of vaccine.
- Self-contained study.
- Duration of the study, per subject: approximately 15 months (screening, enrollment, vaccination, challenge and rechallenge).
- Data collection will be by done at the site.
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Silver Spring, Maryland, United States, 20910
- Walter Reed Army Institute of Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- A male or non-pregnant female 18 to 50 years of age (inclusive) at the time of screening.
- Written informed consent obtained from the subject before screening procedures.
- Free of obvious health problems as established by medical history and clinical examination before entering into the study.*
- Available to participate for duration of study (approximately 15 months).
- If the subject is female, she must be currently using birth control, must be surgically sterilized, or must be at least 1-year post menopausal.
- Pass a comprehension assessment test.
Exclusion Criteria:
- Prior receipt of an investigational malaria vaccine.
- Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 28 days preceding the first dose of study vaccine, or planned use during the study period.
- Administration of chronic immunosuppressants or other immune modifying drugs within six months of vaccination.
- Chronic use of antibiotics with anti-malarial effects.
- Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine(s).
- History of use of anti-malarial medication within 60 days prior to vaccination.
- Any history of malaria.
- Known exposure to malaria within the previous 12 months.
- Planned travel to malarious areas during the study period.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection.
- A family history of congenital or hereditary immunodeficiency.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- Chronic or active neurologic disease including seizures, but not including a single febrile seizure as a child.
- History of splenectomy.
- Acute disease at the time of enrollment.
- Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
- Personal history of autoimmune disease or subjects who describe a first-degree relative with clearly documented autoimmune disease.
- Seropositive for hepatitis B surface antigen.
- Seropositive for Hepatitis C virus (antibodies to HCV).
- Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
- Pregnant or lactating female.
- Suspected or known current alcohol abuse as defined by the American Psychiatric Association in DSM IV.
- Chronic or active intravenous drug use.
- History of severe reactions to mosquito bites as defined as anaphylaxis.
- Female who intends to become pregnant during the study.
- Any history of anaphylaxis in reaction to vaccination.
- A clinical history of sickle cell disease or sickle cell trait.
- Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 10µg dose FMP011
Falciparum Malaria Protein 11 with AS02A adjuvant
|
vaccine
|
Experimental: 50µg dose FMP011
Falciparum Malaria Protein 11 with AS02A adjuvant
|
vaccine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety - Most Frequently Reported Adverse Events and Grade
Time Frame: 30 days post vaccination
|
An AE was defined as any reaction, side effect, or untoward event that occurred during the course of the trial whether or not the event was considered related to study drug or clinically significant. Grade 1: Mild Grade 2: Moderate Grade 3: Severe |
30 days post vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-LSA-1 Antibody Response in Titer Units
Time Frame: days 0, 28, 42 (challenge day) and 84
|
Anti-LSA-1 Antibody Response in Titer Units on days 0, 28, 42 and 84
|
days 0, 28, 42 (challenge day) and 84
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: James F Cummings, MD, Walter Reed Army Institute of Research (WRAIR)
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2006
Primary Completion (Actual)
October 1, 2006
Study Completion (Actual)
April 1, 2007
Study Registration Dates
First Submitted
April 6, 2006
First Submitted That Met QC Criteria
April 6, 2006
First Posted (Estimate)
April 10, 2006
Study Record Updates
Last Update Posted (Actual)
November 26, 2018
Last Update Submitted That Met QC Criteria
May 15, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WRAIR 1249
- HSRRB A-13732 (Other Identifier: USAMRMC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
Clinical Trials on Falciparum Malaria Protein 11 with AS02A adjuvant
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR); The PATH Malaria...CompletedPlasmodium Falciparum MalariaUnited States
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; United States Agency for International Development (USAID); Walter... and other collaboratorsCompleted
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; United States Agency for International Development (USAID); Walter... and other collaboratorsCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsUnited States
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; United States Agency for International Development (USAID); Walter... and other collaboratorsCompleted
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)Completed
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedLung Cancer, Non-Small CellUnited States, Estonia, France, Korea, Republic of, United Kingdom, Germany, Japan, Russian Federation, Poland
-
CSL BehringCompletedHereditary AngioedemaBulgaria, United States, Poland, Spain, Hungary, United Kingdom, Russian Federation, Macedonia, The Former Yugoslav Republic of, Argentina, Australia, Canada, Czech Republic, Israel, Romania, Sweden
-
GlaxoSmithKlineCompleted